Skip to content
RushPR News – Lifestyle
Author:
Jade Biosciences
Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA Nephropathy
May 29, 2026
Jade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody
May 26, 2026
Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy
May 26, 2026
Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 7, 2026
Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 23, 2026
Jade Biosciences Appoints Edward R. Conner, M.D., as Chief Medical Officer
April 22, 2026